{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045791","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.167916+00:00","generated_at":"2026-05-22T03:44:45.144659+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet Biosciences reports Q1 net loss of $18.2M; plans Phase 1 combo trial with resmetirom in 2H 2025","bullets":["Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.","Phase 1 PK trial of denifanstat + resmetirom expected to start 2H 2025; data readout 1H 2026.","End-of-Phase 2 FDA interaction completed Oct 2024; Phase 3 deferred until sufficient funding secured.","Board changes: George Kemble to non-executive Chair; Beth Seidenberg appointed Lead Independent Director; Merdad Parsey to step off June 9, 2025.","License partner Ascletis completed enrollment of 480-patient Phase 3 acne trial in China; topline results expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045791","json":"https://secwatch.observer/filing/0001104659-25-045791.json","markdown":"https://secwatch.observer/filing/0001104659-25-045791.md","text":"https://secwatch.observer/filing/0001104659-25-045791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/0001104659-25-045791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:44:45.144659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}